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Aims. The study aimed to present the experience of a screening programme for early detection of diabetic retinopathy (DR) using
a nonmydriatic fundus camera, evaluating the feasibility in terms of validity, resources absorption, and future advantages of a
potential application, in an Italian local health authority.Methods. Diabetic patients living in the town of Ponzano, Veneto Region
(Northern Italy), were invited to be enrolled in the screening programme. The “no prevention strategy” with the inclusion of
the estimation of blindness related costs was compared with screening costs in order to evaluate a future extensive and feasible
implementation of the procedure, through a budget impact approach.Results. Out of 498 diabetic patients eligible, 80%was enrolled
in the screening programme. 115 patients (34%) were referred to an ophthalmologist and 9 cases required prompt treatment for
either proliferative DR or macular edema. Based on the pilot data, it emerged that an extensive use of the investigated screening
programme, within the Greater Treviso area, could prevent 6 cases of blindness every year, resulting in a saving of €271,543.32
(−13.71%).Conclusions. Fundus images obtained with a nonmydriatic fundus camera could be considered an effective, cost-sparing,
and feasible screening tool for the early detection of DR, preventing blindness as a result of diabetes.
1. Introduction
With the increase in life expectancy, there is, proportion-
ately, a dramatic increase in age-related health conditions
including, in particular, eye diseases. Among all the eye
pathologies, diabetic retinopathy (DR) is currently one of the
leading causes of blindness in the working-age population
in developed countries [1–3]. Epidemiological data show that
the prevalence ofDR is around 30% in the diabetic population
and that the annual incidence varies from 2% to 6% [4].
Every year, up to 1% of diabetic patients develop serious
ocular complications leading to both poor quality of life and
a socioeconomic burden [5].
With regard to the Italian setting, a study conducted in the
Veneto Region, using clinical fundus examination, confirmed
literature data with a prevalence of DR of 26.6% [6]. A
significant worldwide increase in the number of persons
affected by diabetes has been estimated for the next 10
years, reaching approximately 380 million by 2025, mostly in
developing countries. In Europe, compared with 2007, there
is expected to be an increase of 10 million persons with a
prevalence of diabetes below 10% [7].
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As the prevalence of diabetes is expected to rise in the
future, an associated increase in DR cases should also be
expected. However, recently, data suggest that the preva-
lence of DR may decrease, due to the intensification of the
screening programmes and better control of risk-factors, thus
underlying their effectiveness and the significance [8]. In this
view, scholars and practitioners widely agreed that DR, at
any stage of progression, requires specific management: from
the screening programmes (useful for an early diagnosis)
to the definition of pharmacological treatments needed. In
recent years, the strategies for DR prevention have moved
from the traditional ophthalmological examination to a faster
digital retinal imaging acquisition and grading of DR. The
application of these new screening programmes, followed by
prompt diagnosis and a better timely management, is well
known to prevent significantly the risk of diabetic blindness
[9, 10], as well as to decrease all the costs related to the inves-
tigated pathology. In fact, from an economic point of view,
the annual cost per patient affected by DR is approximately
twice as high as those patients with diabetes only [11]: thus,
the implementation of effective and recognized screening
programmes could represent cost-effective strategies [12, 13],
one useful to narrowboth the economic and the social burden
of DR.
Despite the implementation of successful national screen-
ing programmes worldwide, the lack of diffuse screening
activities for DR in Italy is delaying the diagnosis and prompt
treatment of DR.
Public screening programmes and prompt treatments
have been shown to reduce lifetime costs related to visual
disability [14, 15]. For these reasons, vision impairments as
a result of DR should be considered easy to prevent, and the
development of systematic programmes of screening should
represent an urgent and primary healthcare need.
Moving on from these premises, since DR should be one
of the major priorities for the healthcare services, the present
study aimed at investigating the feasibility related to the
introduction of a specific and accurate screening programme
in the catchment area of Treviso (defined as ULSS 9), in
comparison with the “no prevention” strategy, including also
the costs averted to blindness, in terms of the validity of
the intervention and the direct costs absorbed (efficiency)
by the regional healthcare service. The analysis was designed
assuming the regional healthcare service (Veneto Region)
point of view.
2. Materials and Methods
2.1. Study Design. In order to achieve the previously men-
tioned objective, a perspective study for the implementation
of a screening programme devoted to DR was planned
to be performed between September and December 2012,
after receiving the approval from Ethic Committee of the
Local Health Authority. As DR is a multiprofessional and
a multidimensional eye disease, a multidisciplinary group
was involved in the project, including general practitioners,
diabetes experts, administrative staff, nurses, epidemiolo-
gists, and ophthalmologists. The involvement of different
healthcare professionals in the screening programme could
influence the resources absorption and the optimisation of
the screening pathway [12, 13, 16–18].
The screening involved all types (type 1 and type 2) of
diabetic patients living in the area of Ponzano (Treviso)
that has 5.000 inhabitants and is part of one of the Local
Health Authorities of the Veneto Region: the ULSS 9 of
Treviso. Diabetic subjects were accurately identified by cross-
ing different databases: primary and secondary diagnosis for
hospitalisation, drugs and delivery systems, prescriptions,
health care procedures covered by the diabetic code, and the
diabetic code assigned to patients. In particular, the following
patients were invited to attend the screening programme:
(i) outpatients going to a hospital specialist visit to the
diabetologists, or first visit to ophthalmologist; (ii) patients
going to the territorial pharmacist, in order to retrieve the
specific diabetes drugs; and (iii) patients referring to the
general practitioners, with a diagnosis of diabetes. Individuals
whowere already diagnosedwithDRwere not included in the
study.
Initially, a personal letter of invitation was sent to all
the diabetic target population (𝑁 = 498) to be enrolled
in the screening programme. All the patients attending
the screening procedure have signed a specific informed
consent form, consistent with ethical aspects. Screening
for diabetic retinopathy was made using a nonmydriatic
fundus camera. A semiobscured visiting room was used to
optimise physiological mydriasis before each exam. Three
nonmydriatic, 45∘ field, digital retinal images were captured,
in accordance with a previously validated technique. The
three fundus images encompassed the following retinal fields:
field 1 centred on themacula, field 2 centred on optic disc, and
field 3midperipheral superior-temporal field [19].The images
were obtained by trained paramedical staff (in particular,
nurses). All images were electronically transmitted to the
reading centre and stored in an online secured database
called “Eye Knowledge Network” for the second step, online
examination. Retinal images were graded for DR at the
Ca’ Foncello Treviso Hospital, where the Ophthalmology
Unit is located, by two experts and certified readers who
were members of the Reading Centre staff of the University
of Padova. DR and diabetic macular edema (DME) were
graded in accordance with the International Classification
proposed by the American Academy of Ophthalmologists
[20]. When the quality of the images was “inadequate” for
the clinical evaluation and when fundus images were graded
as “positive,” the patients were referred for further oph-
thalmologic examination. “Positive” findings included retinal
changes that required specialist management: moderate and
severe nonproliferative DR, proliferative DR, DME, and/or
any other retinal abnormality. Further ocular and diagnostic
examinations or treatments, if necessary, were then planned.
Fundus imageswere graded as “negative” if noDRor nonsight
threatening DR was detected. A report, with the results of
the screening and the correct follow-up timetable for the
“negative” screened population, was sent to the patient’s
general practitioner within 1 month after the screening.
2.2. Economic Evaluation. From a methodological point of
view, in order to quantify the impact of the introduction of
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screening programme in the clinical practice, both an activity
based costing (ABC) analysis and a budget impact analysis
(BIA) were conducted.
The ABC [21, 22] is useful for the enhancement of the
average costs related to each phase of the screening pathway.
In particular, the main objective of the ABC is the measure-
ment of the costs and the performance activities, taking into
account also the related human and materials resources for
the proper development of the procedure. In this view, the
economic impact of each patient was determined utilising the
following components: (i) human resources (i.e., individuals
involved in the different phases of the screening programme,
such as administrative staff, nurses, and ophthalmologists);
(ii) materials and equipment; (iii) pharmacological and/or
laser treatment. The ABC did not take into consideration
the costs related to the delivery of the invitation letter:
different technologies could be implemented in order to
carry out this task (telephonic invitation, e-mail contact,
personal contact, or letter), differing for the related economic
value.
After the implementation of the ABC, the BIA was
applied. A BIA allows the prediction of the potential financial
impact of a new technology adoption, into a healthcare
system [23]; influencing, in a positive or in a negativemanner,
the healthcare expenditure and considering both a specific
point of view and a determined time horizon. In this view,
two scenarios were simulated, thus comparing the so-called
“do nothing strategy” with the implementation of a proper
screening programme. In particular, in both scenarios, the
occurrence and the related cost of blindness were taken into
consideration as direct healthcare costs. Since the analysis
assumed the Healthcare Regional Services point of view, the
intangible and indirect items of expenditure were excluded
from the study.
The economic analysis used the 2015 Italian Outpatients
and Hospital Admissions Reimbursement Tariffs. Drug costs
were derived from the officially published NHS price list.
If necessary, economic values were reported in “euros,”
considering the 2015 inflation rate, using the Consumer Price
Index for healthcare expenditure, thus making economic
measures comparable, and being based on the same year of
reference.
In order to ensure the robustness of the result, a sensitivity
analysis was carried out. In particular, both the attendance
rate to the screening programme and the percentage of
patients undergoing the complete eye examination were
modified, thus understanding if significant changes in the
feasibility of the programme occur.
Literature reported that patients’ compliance with DR
screening is not optimal worldwide, hence reporting atten-
dance rates ranging from a minimum of 32% and a maxi-
mum of 92% [24–27]. Further analysis reported a variation
in the eye examination rate. The Local Health Authority
involved declared that it could reach about the 80%–85% if
collaboration with community-based organisations, as well
as greater information activities of DR risks among citizens,
is implemented.
Moving on from these premises, 4 different analyses were
performed.
3. Results
3.1. The Sample under Assessment. 498 individuals were
identified as being diabetic patients within the area of
Ponzano (that has 5,000 inhabitants); thus, it emerged that
the prevalence of the diabetes in the investigated town was
around 10%.
Out of the 498 diabetic patients originally invited to enroll
in the screening programme, 340 accepted to be evaluated
(68%), although it was possible to confirm a response rate
equal to 80% since 57 patients did not attend the screening
programme because they had already undergone a complete
eye examination that showed no signs of DR development.
No patients with a previous DR diagnosis were enrolled in
the present study.
The study population was composed predominantly of
males (55%); the average age of the sample was 68 years
(range: 26–93). On average, patients have been suffering from
diabetes for 20 years (range: 2–41).Themost common comor-
bidities developed by patients were hypertension (40%) and
dyslipidaemia (38%). 324 patients (95%) successfully com-
pleted the procedure, though in 16 cases (5%) images were
noncaptured due to either systemic conditions of the patients,
insufficient mydriasis, or other technical reasons related to
the fundus camera.The quality of digital images was adequate
for the interpretation in 260 patients (80%), although it was
ungradable in 64 cases (20%) due to insufficient dilation,
media opacity, poor fixation, or the absence of one of the
captured fields.
As a result, taking into account the gradable 260 patients,
225 were classified as “negative” (87%) and 35 as “positive”
(13%). Based on the entire screened population, 115 patients
(34%) were referred to an ophthalmologist. Of these, 16
(14%) were patients from whom it was impossible to obtain
images, 64 (56%) had no evaluable images, and 35 (30%)were
“positive” cases.
Of the previously mentioned 115 patients, 92 (91%)
underwent a full ophthalmological examination, giving the
following results: in 67 cases (73%), DR was not detected,
though 25 patients (27%) presented signs ofDR. In particular,
24% (𝑁 = 6) had mild nonproliferative DR, 52% (𝑁 =
13) had moderate nonproliferative DR, 12% (𝑁 = 3) had
preproliferative DR, and 12% (𝑁 = 3) had proliferative DR.
Concomitant DME was present in 36% (𝑁 = 9) of these
patients.
In 9 cases (36%), prompt treatment with intravitreal
injections and/or laser photo-coagulation was required for
proliferative and severe preproliferative retinopathy or mac-
ular edema.
3.2. Results from the Study Conducted in Ponzano. After
these general remarks, regarding the screened population,
an economic evaluation was required in order to investigate
the amount of resources dedicated for this specific innovative
programme.
It should be noted that the Veneto Region 2015 tariffs
were taken into account in order to investigate the value of
the complete screening programme, thus also including the
entire cycle of intravitreal injections.
4 Journal of Ophthalmology
Table 1: Cost of the screening programme, distinguished by phases.
Phases Humanresources
Materials
and
equipment
Drugs Total
Phase I €1,056.23 €2,112.46 — €3,168.69
Phase II €1,170.98 €1,170.39 — €2,341.37
Phase III €3,109.10 — — €3,109.10
Phase IV — — €27,280.65 €27,280.65
Total €35,899.81
With reference to the abovementioned distribution of the
patients, the economic resources absorption, with regard to
thewhole population screened pathway, was divided into four
distinct and logical phases:
(i) 340 patients attended the screening programme,
involving 1 healthcare professional (nurse) who spent
12minutes per patient and considering the equipment
amortization.
(ii) 324 patients completed the procedure, after which
1 ophthalmologist interpreted their digital images,
spending about 5 minutes per patient, considering
also theworkstation and the administrative staff costs.
(iii) out of the 115 patients referred for a complete exami-
nation, only 92 underwent an ophthalmology exami-
nation, in order to obtain an in-depth analysis of the
disease (in the third phase, it is important to note that
the costs of all the materials and the drugs utilised by
the clinicians for the complete eye examination are
included in the “first visit” reimbursement tariff).
(iv) Nine patients, who were suffering from a severe stage
of pathology, received pharmacological and/or laser
treatment, thus considering that both the human
resources and the materials/equipment costs are
included in the procedure costs, as detailed in Table 2.
It was first necessary to evaluate the costs related to the human
resources involved in the screening programme. Thus, the
gross monthly salary, related to each specific professional
title, was taken into consideration. In particular, its time value
per minute was multiplied by the time dedicated to each
procedure.
Table 1 shows the categories of cost impacting on each
phase and the total cost per phase.
Table 1 shows that the fourth phase absorbed the most
part of the economic resources, presenting the economic
evaluation of the treatment for 9 patients. In particular,
three groups of patients suffering from RD or DME were
considered: (i) 4 patients (45.5%) received a therapeutic
cycle of intravitreal injections with Ranibizumab alone; (ii)
3 individuals (30%) received laser treatment as a support of
Ranibizumab injection; and (iii) 24.5% (2 patients) received
Dexamethasone, thus being consistent with literature and
real-life data [28]. Treatment costs were related to a period of
12 months, in which clinicians administered to the patients
a cycle composed of, on average, 3.61 (Ranibizumab) or
1.3 (Dexamethasone) intravitreal injections, based on the
observation of the clinical pathway of the nine patients
under investigation in the health authority of reference and
consistent with other national and international literature
evidence [28, 29]. No surgical interventions were performed
in the observed population.
Costs for an intravitreal injection were distinguished
as follows: (a) the cost of the specific drug (€644.73 for
Ranibizumab and €951.75 for Dexamethasone) and (b) the
cost of the procedure carried out by the health authority of
reference (€290.00, independently of the administered drug).
Patients performing laser therapy absorbed an additional cost
equal to €81.28 for every single procedure.
The costs related to these two treatment phases are
detailed in Table 2.
With reference to Tables 1 and 2, the amount of all the
screening costs for patients within the area of Ponzano was
equal to €35,899.81, treating the 340 patients who attended
the programme.
3.3. Results from the Economic Evaluation Testing the Fea-
sibility of the Screening Programme in the Grater Treviso
Catchment Area. After the costs of the screening programme
phases had been calculated, the prevention activity was then
extended to the Treviso catchment area (considering the
whole ULSS 9), in order to estimate the feasibility of the
screening procedure in a larger population.
This area presents 22,000 estimated diabetes cases. If the
response rate was the same as that in the pilot study (80%),
17.600 patientswould be expected to attend the screening pro-
gramme within the first year. Considering an average work
shift of 7 hours per day, a single nurse, completely devoted to
the screening activities, could be able to perform about 7,000
procedures per year. With regard to the ophthalmologist and
the administrative staff, assuming an average work shift of 8
hours, it emerges that the clinician could produce on average
9,600 medical reports per year, and the administrative staff
could generate a maximum amount of 19,200 documents
per year. As a result, 3 members of the paramedical staff
(nurses), 2 ophthalmologists, and 1 administrative would
also be required to treat the abovementioned attending
patients.
Investment in the required equipment would be made to
cover the need of the expected diabetic citizens; in particular,
it should be allocated to 5 pieces of equipment, thus requiring
an overall investment of €72,000.
Considering the incidence of blindness as a result of DR
(0.002% per year, taking into account the whole ULSS 9 that
has 419,728 inhabitants), 8 new cases every year would be
expected if the screening programme was not applied. The
screening programme conducted reported an effectiveness
equal to 74.59%, calculated as the difference between individ-
uals attending the screening programme and individuals who
did not participate in the prevention activities, or patients
who denied to go to the ophthalmologist for the complete eye
examination. Considering the Treviso catchment area, 4,400
individuals did not attend the screening programme whereas
1,190 did not perform the in-depth visit, thus reaching a total
amount of 5,590 individuals (25.41% of the overall invited
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Table 2: Details of the treatment’s costs.
Treatment option Cost of the drugadministered Procedure
Total cost for a
single injection
Total cost for a
therapeutic cycle
Total cost for the
treated population
(9 patients)
Ranibizumab +
laser therapy €644.73 €371.28 €1,016.01 €3,667.80 €9,903.07
Ranibizumab €644.73 €290.00 €934.73 €3,374.38 €22,928.93
Dexamethasone €951.75 €290.00 €1,241.75 €1,614.28 €3,559.48
Table 3: Economic resources related to the investigated procedures.
Screening programme pathway
Phase I €164,026.11
Phase II €121,230.90
Phase III €160,924.94
Phase IV (treatment) €1,154,724.70
Investment in equipment €72,000.00
Blindness €35,843.46
Total €1,708,750,11
“Do nothing” strategy
Blindness €134,424.00
Treatment €1,845,869.43
Total €1,980,293.43
Economic savings −€271,543.32
−13.71%
population). In this view, in the innovative scenario, only 2
patients would develop blindness.
Literature evidence [30] shows that the cost of blindness is
approximately $18,670 (i.e., €16,803), including only medical
and direct costs.
In addition, therapeutic treatment should be adminis-
tered to 8% of DR patients, considering both the screening
pathway and the “no prevention” strategy. In particular,
381 patients referring to the screening pathway scenario
and 609 patients (thus considering a DR occurrence rate
equal to 34.60% [31] within the diabetic population) for
whom “no prevention” strategy was implemented received
drugs therapy. The distribution of the treated population,
considering the administered drug (74.5% for Ranibizumab
alone or with the support of laser therapy and 25.5% for
Dexamethasone [28, 29]), as well as the treatment frequency
within a 12-month time horizon, was assumed to be the same
as the conducted study previously described.
With reference to these data, the total costs of the two
different pathways are presented in Table 3. In this view, it
emerged that in both scenarios themore significant economic
resources absorption was related to the treatment phase: at
12-month time horizon, the administration of Ranibizumab
with the support of laser therapy, Ranibizumab alone, or
Dexamethasone required, on average, €3,667.80, €3,374.38,
and €1,614.28, respectively, per patient.
Table 4 reports the results of the sensitivity analyses,
demonstrating an overall economic advantage in all the
cases in which the prevention activity is implemented, thus
ensuring the robustness of the BIA result. In particular,
it emerged that the economic benefits of the screening
programme implementation are more sensitive to the higher
number of screened individuals, in comparison with the
decrease of the blindness events that occurred.
More investments are required from the healthcare
service, if the screening programme would cover a larger
number of the target population: in particular, achieving
a maximum attendance rate equal to 92%, the healthcare
service would equally benefit of an economic saving of
−2.38%, always resulting in the preferable solution.
4. Discussion
Screening for diabetic retinopathy is important because the
majority of patients who develop DR show no symptoms
until diabetic macular edema and/or proliferative diabetic
retinopathy are present, thus confirming that, in the early
stages of the investigated disease, any notable symptoms affect
the patients.
Although the beginning of the DR has an asymptomatic
nature, the attendance rate reported in the proposed study
was equal to 80%, thus demonstrating the effectiveness and
the validity of the screening programme. An increase in the
attendance rate could be achievedwith an improvement and a
diversification of the communication tools to inform patients
concerning the importance of the eyes examinations and
controls, thus enhancing their awareness on this field. In par-
ticular, literature [32] reported that telehealth or telemedicine
programmes may facilitate early DR diagnosis and timely
treatment, preserving vision.
The results of the study show the importance of a screen-
ing programme, from an economic point of view, one leading
to a substantial saving of €271,543.32 (−13.71%) in compari-
son with the “no prevention” strategy. In addition, three-field
colour, 45-degree, nonmydriatic images have demonstrated a
sensitivity and specificity of 82% and 92%, respectively, in the
diagnosis of DR, representing an effective tool in a screening
setting [19].
Traditionally, ophthalmologists evaluate patients for DR
by mydriatic indirect ophthalmoscopy. The references for
the correct follow-up and management are the AAO and
national guidelines for DR [33, 34]. However, despite the
relevance of implementing a screening programme, in the
real world, these recommendations are seldom adhered to.
The increasing number of diabetic patients, in particular
due to the population ageing, delays access to the next
ophthalmologic examination. It has been estimated that only
50% of the known diabetic patients receive the recommended
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Table 4: Sensitivity analyses.
Sensitivity
analysis
Screening
attendance rate Eye examination rate “To do nothing” strategy
Screening programme
pathway Difference (€) Difference (%)
Sensitivity
analysis I 32% 75% €1,980,293.43 €811,332.32 −€1,168,961.11 −59.03%
Sensitivity
analysis II 92% 75% €1,980,293.43 €1,933,104.55 −€47,188.87 −2.38%
Sensitivity
analysis III 80% 85% €1,980,293.43 €1,789,070.03 −€191,223.39 −9.66%
Sensitivity
analysis IV 80% 90% €1,980,293.43 €1,869,389.96 −€110,903.47 −5.60%
regular eye examinations [35], something that may be con-
sidered a real concern. Eye screening offers the possibility
of identifying the early signs of DR, thus preventing visual
loss due to DME. As previously described, new technological
screening procedures based on digital mydriatic and nonmy-
driatic fundus images present multiple advantages. Images
can be taken by trained nonspecialist operators and can be
viewed “online” by specifically trained ophthalmologists in
a deferred time, thus sparing and optimising resources. This
could lead to a significant benefit with the decreasing of
waiting lists, a phenomenon perceived by citizens as a serious
problem of modern healthcare systems that compromises
the coverage of their health needs. In addition, because of
their easy and safe use, without the administration of drugs,
nonmydriatic cameras can be placed in primary care settings
in order to improve the access to care.
A large-scale application of this screening strategy could
spare unnecessary examinations for “negative” patients, thus
preventing irreversible loss of visual acuity for persons
affected by retinopathy, due to long waiting lists for eye
examination.
In particular, it emerged that the screening programme
presented in the study has the potential to reduce the
prevalence of blindness due to DR in the Veneto Region.
With reference to this, the nonmydriatic fundus camera
is not only effective but also cost-effective in the investigated
greater area and leads to significant benefits for both the
regional healthcare service and for the patients. Vision loss
is associated not only with a large increase of costs due to the
management of this condition but also with the compromise
of a patient’s quality of life, thus representing a significant
social burden and requiring a future in-depth analysis. In
fact, with the rapid ageing of the population, and considering
that older adults could stay active and also productive in
this specific part of their lives, blindness should be a public
healthcare priority.
Healthcare regulators and policymakers will benefit from
the implementation of adequate screening programmes, opti-
mising effectiveness and resources allocation within this spe-
cific target population. In this view, the present study would
represent the first attempt to extent the current theories and
models into the practical context of the healthcare sector,
extending the results of the study, from the Italian setting
to other European and international contexts. The results
would contribute in the advancement and establishment of
organisational and management models to be applied in the
prevention sector, freeing up hospital resources for more
severe cases of patients and reducing the economic and
social burden of waiting lists for ophthalmic procedures.
The early diagnosis and the process of taking charge of
the patients could be considered an effective way to offer a
better healthcare delivery to the patients, a clinical pathways
optimisation but, in particular, a possible economic saving for
the healthcare services.
A future interesting contribution for policy makers could
be also the definition of the best screening programme
organisational setting, maximizing both effectiveness and
efficiency, involving different healthcare professionals, such
as general practitioners and pharmacists. New approaches to
the screening development could reduce healthcare expendi-
ture and increase the attendance rate for patients.
In this view, further researches could be addressed to the
proposal of a reimbursement tariff for the diabetic screening
activities, with reference to different clinical setting in which
the procedure could be performed, as well as the imple-
mentation of a multidimensional assessment (through the
health technology assessment tool) in order to understand all
the possible implications (organisational, social, and equity
aspects) of the adoption of screening programmes, measured
into the clinical practice, generating significant advancement
to these findings and their robustness.
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